Getting Started on CINRYZE® (C1 esterase inhibitor [human]) Therapy

Talk to your doctor

Discuss CINRYZE® (C1 esterase inhibitor [human]) therapy and CINRYZESolutions® with your doctor.

Contact the CINRYZESolutions Programs

Call CINRYZESolutions at 1-877-945-1000 (either you or your doctor can make the first call). You will be assigned a Patient Care Coordinator (PCC) who will explain how the Patient Service Center (PSC) can assist with getting you on CINRYZE therapy and how to enroll in CINRYZESolutions.

Complete the CINRYZE® (C1 esterase inhibitor [human]) Prequalification Form

Fill out the CINRYZE Prequalification Form and then fax it to the PSC at 1-888-281-8211. Please note that your insurance company may require additional documentation to authorize coverage for CINRYZE® (C1 esterase inhibitor [human]).

Next steps

As soon as the Prequalification Form is processed at the PSC, a PCC will reach out to both you and your doctor to discuss your case and the status of your insurance coverage, and will advise on the next steps in receiving therapy.

Should you or your doctor have any questions, call the CINRYZESolutions Programs toll free at 1-877-945-1000 or send an email to inquiries@cinryzesolutions.com. CINRYZESolutions is available Monday through Friday, 8:00 am to 7:00 pm EST.

Connect with an HAE Mentor

Join the CINRYZEConnect™ Program to connect with a mentor who's also living with HAE.

Find out more ›

Real Patients Talk About HAE

It helps to be reminded that you’re not alone. Hear first-hand stories from individuals who have HAE.

Hear Jason tell his story ›

Indication
CINRYZE® (C1 esterase inhibitor [human]) is an injectable medicine that is used to help prevent swelling and/or painful attacks in teenagers and adults with Hereditary Angioedema (HAE).

Important Risk Information
You should not use CINRYZE if you have had life-threatening immediate hypersensitivity reactions, including anaphylaxis to the product.

Tell your healthcare provider about all of your medical conditions, including if you:

  • Are pregnant or planning to become pregnant. It is not known if CINRYZE can harm your unborn baby.
  • Are breastfeeding or plan to breastfeed. It is not known if CINRYZE passes into your milk and if it can harm your baby.
  • Have a history of blood clotting problems. Very high doses of C1 esterase inhibitor could increase the risk of blood clots.

Tell your healthcare provider and pharmacist about all of the medicines you take, including all prescription and non-prescription medicines such as over-the-counter medicines, supplements, or herbal remedies.

Allergic reactions may occur with CINRYZE. Call your healthcare provider or get emergency support services right away if you have any of the following symptoms:

  • wheezing
  • difficulty breathing
  • chest tightness
  • turning blue (look at lips and gums)
  • fast heartbeat
  • swelling of the face
  • faintness
  • rash
  • hives

Because CINRYZE is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

The most common side effects seen with CINRYZE were headache, nausea, rash, and vomiting. These are not all the possible side effects of CINRYZE. Tell your healthcare provider about any side effect that bothers you or that does not go away. You can also report side effects to ViroPharma Medical Information at (866) 331-5637 or the FDA at 1-800-FDA-1088.

Medicines are sometimes prescribed for purposes other than those listed here. Do not use CINRYZE for a condition for which it is not prescribed. Do not share CINRYZE with other people, even if they have the same symptoms that you have.

Before starting CINRYZE, please read the accompanying Patient Information carefully and each time you get a refill. This information does not take the place of talking with your healthcare provider, and it does not include all of the important information about CINRYZE. If you have questions after reading this, ask your healthcare provider.

Please see the accompanying Full Prescribing Information.

Was this content
 useful to you?